October 27, 2016—Healthcare payers expect claims costs for specialty and biotech drugs to rise by almost 20 percent next year, a leading health benefits consulting firm says.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)